Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2020 Nov 1.

Published in final edited form as: Acta Oncol. 2019 Jul 26;58(11):1634–1639. doi: 10.1080/0284186X.2019.1645354

Table 2.

Metastatic site correlation with positive ctDNA.

Metastatic site	ctDNA T790M positive	Unadjusted P-value
Pleura	37% (36/98) with metastases vs.	0.14
Pleura	25% (20/79) without	0.14

Lymph node	38% (35/92) with metastases vs.	0.07
Lymph node	25% (21/85) without	0.07

Bone	45% (41/92) with metastases vs.	0.0002
Bone	17% (15/85) without	0.0002

Liver	38% (19/50) with metastases vs.	0.28
Liver	29% (37/127) without	0.28

Adrenal	39% (7/18) with metastases vs.	0.60
Adrenal	31% (49/159) without	0.60

Brain	42% (22/53) with metastases vs.	0.08
Brain	27% (34/124) without	0.08

Abbreviation: ctDNA, circulating-tumor DNA.

Note: The Bonferroni-adjusted significance threshold was set at P=0.008.